---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-062628"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T11:45:41.575658+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ABVC signs binding term sheet for China license of MDD/ADHD drugs; up to $20M in fees plus royalties

## Summary
- Binding term sheet with Xinnovation Therapeutics for exclusive license of ABV-1504 (MDD) and ABV-1505 (ADHD) in mainland China.
- Potential aggregate income of $20M in licensing fees plus royalties of 5-12% of net sales.
- Final definitive agreement expected within one year; subject to due diligence, regulatory approvals, board approval.
- Xinnovation will bear all costs for clinical trials and product registration in China.
- ABVC states royalty revenue could reach ~$50M annually and ~$1B over patent life if expected sales achieved.

## SEC filing metadata
- accession: 0001213900-23-062628
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/0001213900-23-062628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/ea182689-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-062628
- JSON: https://secwatch.observer/filing/0001213900-23-062628.json
- Plain text: https://secwatch.observer/filing/0001213900-23-062628.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Term Sheet with Xinnovation Therapeutics Co., Ltd. (effective 2023-07-31).
  - Action: entry
  - Agreement: license
  - Counterparty: Xinnovation Therapeutics Co., Ltd.
  - Effective: 2023-07-31
  source text: On July 31, 2023, the Company entered into a binding term sheet (the “Term Sheet”) with Xinnovation Therapeutics Co., Ltd., a Company incorporated under the Law of People’s Republic of China (“Xinnovation”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/0001213900-23-062628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.